about
Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?Epigenetic inactivation of ST6GAL1 in human bladder cancer.Clinical Implications and Prognostic Values of Prostate Cancer Susceptibility Candidate Methylation in Primary Nonmuscle Invasive Bladder Cancer.DNA methylation of GSTP1 in human prostate tissues: pyrosequencing analysisPyrosequencing Analysis of APC Methylation Level in Human Prostate Tissues: A Molecular Marker for Prostate Cancer.Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinomaEpigenetic therapy in urologic cancers: an update on clinical trials.Methods for the discovery of low-abundance biomarkers for urinary bladder cancer in biological fluids.Hypermethylation in bladder cancer: biological pathways and translational applications.Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers.Noninvasive approaches for detecting and monitoring bladder cancer.Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.Alterations of histone H1 phosphorylation during bladder carcinogenesisClinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling.Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.Identification of Core Genes and Key Pathways via Integrated Analysis of Gene Expression and DNA Methylation Profiles in Bladder Cancer.
P2860
Q26744146-78236D9B-D66C-4828-912B-07CB6F765604Q34695132-490013F8-7D58-44E8-B1FD-6D6C3FA4ADFEQ35649706-0B7ED56A-5308-4FA4-A076-D8406591124EQ35852010-375869D4-986D-4849-9F79-6C1F775ACBADQ36705589-409A5F1B-2B44-4C44-8FD3-3ACFAF48CA14Q36823682-7DC1A4FA-C926-4659-B3BB-108C60E57605Q37707110-50834AC0-B398-40A4-B314-9DE5232926FCQ37810251-C82F74B0-D9E4-4636-8761-0342F55482F9Q37978544-7EB3B67A-80C1-469E-A8A2-F8606FA4F9DCQ38068225-D6F9C45B-D3BE-49AC-B5F5-C36B1975F232Q38286089-CE921AB2-AA21-46B4-AC4E-B5ECE3871A5BQ38297729-B7A8B758-292C-4BF4-A440-4D93BEA1C2DAQ39151691-B039820F-E805-4693-A261-BC5291357A21Q44045391-08812066-95F9-421F-8F27-87C29D32331CQ45716446-AA2B6015-5024-4080-AAAC-005BBF2364D3Q54376271-E95C3250-1050-4CD2-8F67-D13F517A79E4Q55158192-C5D27915-C7CE-4435-9B0E-24B5F22C08BF
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epigenetic biomarkers in urothelial bladder cancer.
@en
Epigenetic biomarkers in urothelial bladder cancer.
@nl
type
label
Epigenetic biomarkers in urothelial bladder cancer.
@en
Epigenetic biomarkers in urothelial bladder cancer.
@nl
prefLabel
Epigenetic biomarkers in urothelial bladder cancer.
@en
Epigenetic biomarkers in urothelial bladder cancer.
@nl
P2860
P356
P1476
Epigenetic biomarkers in urothelial bladder cancer.
@en
P2093
Wun-Jae Kim
Yong-June Kim
P2860
P304
P356
10.1586/ERM.09.5
P577
2009-04-01T00:00:00Z